These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20101393)

  • 21. Male and female ecstasy users: differences in patterns of use, sleep quality and mental health outcomes.
    Ogeil RP; Rajaratnam SM; Broadbear JH
    Drug Alcohol Depend; 2013 Sep; 132(1-2):223-30. PubMed ID: 23453259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction between the 5-HTTLPR serotonin transporter polymorphism and environmental adversity for mood and anxiety psychopathology: evidence from a high-risk community sample of young adults.
    Laucht M; Treutlein J; Blomeyer D; Buchmann AF; Schmid B; Becker K; Zimmermann US; Schmidt MH; Esser G; Rietschel M; Banaschewski T
    Int J Neuropsychopharmacol; 2009 Jul; 12(6):737-47. PubMed ID: 19154632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
    Fisk JE; Montgomery C; Murphy PN
    Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of acute tryptophan depletion on mood and impulsivity in polydrug ecstasy users.
    Young SN; Regoli M; Leyton M; Pihl RO; Benkelfat C
    Psychopharmacology (Berl); 2014 Feb; 231(4):707-16. PubMed ID: 24142202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?
    Alati R; Kinner SA; Hayatbakhsh MR; Mamun AA; Najman JM; Williams GM
    Drug Alcohol Depend; 2008 Jan; 92(1-3):108-15. PubMed ID: 17850992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in prefrontal blood oxygenation during an acute multitasking stressor in ecstasy polydrug users.
    Roberts CA; Wetherell MA; Fisk JE; Montgomery C
    Psychol Med; 2015 Jan; 45(2):395-406. PubMed ID: 25066866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
    Keyes KM; Martins SS; Hasin DS
    Drug Alcohol Depend; 2008 Sep; 97(1-2):139-49. PubMed ID: 18524499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrophysiological evidence of atypical processing underlying mental set shifting in ecstasy polydrug and polydrug users.
    Roberts CA; Fairclough SH; McGlone FP; Fisk JE; Montgomery C
    Exp Clin Psychopharmacol; 2013 Dec; 21(6):507-15. PubMed ID: 24080019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.
    Pirona A; Morgan MJ
    J Psychopharmacol; 2010 Feb; 24(2):175-85. PubMed ID: 19351799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.
    Verheyden SL; Maidment R; Curran HV
    J Psychopharmacol; 2003 Dec; 17(4):371-8. PubMed ID: 14870948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disrupted 'reflection' impulsivity in cannabis users but not current or former ecstasy users.
    Clark L; Roiser JP; Robbins TW; Sahakian BJ
    J Psychopharmacol; 2009 Jan; 23(1):14-22. PubMed ID: 18515464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressant-like effects of ecstasy in subjects with a predisposition to depression.
    Majumder I; White JM; Irvine RJ
    Addict Behav; 2012 Oct; 37(10):1189-92. PubMed ID: 22704044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mental disorders in ecstasy users: a prospective-longitudinal investigation.
    Lieb R; Schuetz CG; Pfister H; von Sydow K; Wittchen H
    Drug Alcohol Depend; 2002 Oct; 68(2):195-207. PubMed ID: 12234649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.
    Fagundo AB; Cuyàs E; Verdejo-Garcia A; Khymenets O; Langohr K; Martín-Santos R; Farré M; de la Torre R
    J Psychopharmacol; 2010 Sep; 24(9):1381-93. PubMed ID: 20080926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users.
    Parrott AC; Sisk E; Turner JJ
    Drug Alcohol Depend; 2000 Jul; 60(1):105-10. PubMed ID: 10821995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
    Daumann J; Till B; Fischermann T; Rezk M; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modifiable risk factors of ecstasy use: risk perception, current dependence, perceived control, and depression.
    Leung KS; Ben Abdallah A; Copeland J; Cottler LB
    Addict Behav; 2010 Mar; 35(3):201-8. PubMed ID: 19880258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ecstasy exposure & gender: examining components of verbal memory functioning.
    Price JS; Shear P; Lisdahl KM
    PLoS One; 2014; 9(12):e115645. PubMed ID: 25545890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.